Начало › Плоскоклетъчен карцином на главата и шията › Тексас › Houston
Клинични проучвания за Плоскоклетъчен карцином на главата и шията в Houston, TX
47 проучвания за Плоскоклетъчен карцином на главата и шията търсят участници в обекти в и около Houston (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Набиране на участнициФаза 1
- University of Texas MD Anderson Cancer Center, Houston
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Набиране на участнициФаза 2/3
- Site#0102, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Набиране на участнициФаза 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Набиране на участнициФаза 1
- ALX Center 5, Houston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Набиране на участнициФаза 1
- Research Site, Houston
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Набиране на участнициФаза 3
- MD Anderson Cancer Center, Houston
Intratumoral N17350 in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Набиране на участнициФаза 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- M. D. Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Research Site, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Набиране на участнициФаза 1
- Normunity Investigational Site, Houston
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Набиране на участнициФаза 2/3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Michael E DeBakey VA Medical Center, Houston
- UT MD Anderson Cancer Center, Houston
- и още 1
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Houston Methodist Hospital, Houston
SMP-3124LP in Adults With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
Набиране на участнициФаза 2
- M D Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Oncology Consultants, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Набиране на участнициФаза 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Набиране на участнициФаза 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Набиране на участнициФаза 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Набиране на участнициФаза 1
- MD Anderson, Houston
- NEXT Texas LLC - Houston, Houston
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.
Набиране на участнициФаза 4
- MD Anderson Cancer Center, Houston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Набиране на участнициФаза 1
- University of Texas MD Anderson Cancer Center /ID# 252004, Houston
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Набиране на участнициФаза 1
- M D Anderson Cancer Center, Houston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 2
- USA12-0, Houston
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Набиране на участнициФаза 3
- MD Anderson Cancer Center, Houston
- Oncology Consultants, Houston
A Study of VET3-TGI in Patients With Solid Tumors
Набиране на участнициФаза 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Набиране на участнициФаза 1
- Baylor St. Luke's Medical Center, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Набиране на участнициФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
Набиране на участници
- Baylor College of Medicine, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Набиране на участнициФаза 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Набиране на участнициФаза 1/2
- M.D. Anderson Cancer Center, Houston
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Набиране на участнициФаза 3
- University of Texas, MD Anderson Cancer Center, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
Проучвания за Плоскоклетъчен карцином на главата и шията в други градове
- Los Angeles, CA42 проучвания
- Boston, MA40 проучвания
- New York City, NY39 проучвания
- Nashville, TN39 проучвания
- St. Louis, MO28 проучвания
- Arlington, VA26 проучвания
- Philadelphia, PA26 проучвания
- Chicago, IL26 проучвания
- Atlanta, GA24 проучвания
- San Antonio, TX22 проучвания
- New Haven, CT22 проучвания
- Pittsburgh, PA22 проучвания
Други проучвания в Houston
- Рак на белия дроб с недребноклетъчен тип145 проучвания
- Рак на гърдата126 проучвания
- Рак (всички видове)121 проучвания
- Метастатичен рак104 проучвания
- Колоректален рак102 проучвания
- Рак на яйчниците89 проучвания
- Остра миелоидна левкемия85 проучвания
- Рак на белия дроб78 проучвания
- Рак на простатата76 проучвания
- Ендометриален рак68 проучвания
- Рак на панкреаса61 проучвания
- Меланом59 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.